Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy

Date
2020-10-07
Authors
Ward, Jessica
Kussin, Efrem
Ward, Jessica
Tropf, Melissa
Tou, Sandra
DeFrancesco, Teresa
Keene, Bruce
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Research Projects
Organizational Units
Veterinary Clinical Sciences
Organizational Unit
Journal Issue
Series
Department
Veterinary Clinical Sciences
Abstract

Background Pimobendan is frequently used off‐label for treatments of cats with congestive heart failure (CHF). Concern exists regarding the safety of pimobendan in cats with outflow tract obstruction (OTO).

Objectives In cats treated with pimobendan, incidence of adverse effects will not differ between cats with OTO vs cats with nonobstructive cardiomyopathy.

Animals Two‐hundred sixty cats with CHF (57 with OTO, 203 with nonobstructive disease).

Methods Retrospective medical record review. Groups were compared using 2‐sample t‐tests, Wilcoxon rank‐sum tests, and Fisher exact tests.

Results Compared to cats with nonobstructive cardiomyopathy, cats with OTO were younger (8.9 [interquartile range (IQR) 6.6] vs 10.8 [6.3] years, P = .0036), more likely to have a heart murmur (51/57 [90%] vs 76/203 [37.8%] cats, P < .0001), more likely to manifest CHF as pulmonary edema (53/57 [83%] vs 144/203 [70.9%] cats, P = .0004), and less likely to have pleural effusion (19/57 [33%] vs 122/203 [60.1%] cats, P = .0005). Adverse effects suspected to be related to pimobendan administration occurred in 12/260 cats (4.6%), including 11/203 cats (5.4%) with nonobstructive cardiomyopathy and 1/57 cat (2%) with OTO (P = .7). Pimobendan was discontinued due to adverse effects in 4/260 cats (1.5%), 3 with nonobstructive disease and 1 with OTO (P = 1.0). Acute adverse hemodynamic effects after pimobendan administration were not detected in any cats.

Conclusions and Clinical Importance Pimobendan is well tolerated in cats with cardiomyopathy and CHF, regardless of the presence of OTO.

Comments

This is the published version of the following article: Ward, Jessica L., Efrem Z. Kussin, Melissa A. Tropf, Sandra P. Tou, Teresa C. DeFrancesco, and Bruce W. Keene. "Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy." Journal of Veterinary Internal Medicine. DOI: 10.1111/jvim.15920. Posted with permission.

Description
Keywords
Citation
DOI
Collections